FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005098585> ?p ?o ?g. }

• W2005098585 endingPage "1123" @default.
• W2005098585 startingPage "1115" @default.
• W2005098585 abstract "This laboratory has previously published on phosphorodiamidate morpholino (MORF) pretargeting of tumor in which an anti-tumor antibody conjugated with MORF (a DNA analogue) is first administered, followed at a later time by the radiolabeled complementary MORF (cMORF) as the effector. In the present study, the pharmacokinetics of the antibody and effector were measured under different conditions in mice to establish their quantitative relationships with tumor accumulations by pretargeting. A cytosine-free 18 mer cMORF was conjugated with MAG3 for 99mTc labeling while the anti-CEA antibody MN14 was conjugated with DTPA for 111In labeling and with MORF to impart binding affinity for radiolabeled cMORF. Mice bearing LS174T thigh tumors were used to study: (1) the pharmacokinetics of MN14-MORF by administering 111In-MN14 at doses between 10 and 100 μg with sacrifice at 2 days and at 30 μg with sacrifice between 1 and 3 days; (2) the biodistribution of 99mTc-cMORF following one to four injections (containing 0.15 μg each and separated by 1 h) to animals having received 30 μg of antibody–MORF 2 days earlier and with sacrifice at 3 h after the final injection; and (3) the influence on the biodistribution of 99mTc-cMORF of a 2 to 4 day interval between the administration of 30 μg of antibody–MORF and 0.30 μg of 99mTc-cMORF. (1) The biodistribution of antibody in percent accumulation (%ID or %ID/g) was largely independent of antibody dose but the absolute accumulation of antibody in tumor increased linearly with dose, showing no evidence of tumor saturation of CEA sites by MN14. Over 1–3 days post antibody administration, blood levels of radiolabeled antibody decreased as expected; however, tumor levels remained constant, thus showing an absence of antibody clearance in tumor over this period. (2) With fixed antibody–MORF dose and increasing number of injections of 99mTc-cMORF, cumulative percent blood levels steadily decreased in agreement with the values calculated based on the antibody–MORF in blood. In contrast, cumulative percent tumor levels stayed fairly constant over the first two injections. Thus the antibody–MORF in tumor became saturated with cMORF more slowly than that in blood owing to delivery differences. (3) As expected, percent blood levels decreased with increasing interval between injections of antibody–MORF and 99mTc-cMORF. The percent tumor accumulation, however, remained constant over the 3 day interval, thus demonstrating only slow loss of MORF expression in situ. The 99mTc-cMORF accumulation in tumor after saturation was mathematically determined based on the antibody–MORF concentration in tumor while the blood levels of 99mTc-cMORF were determined based on the concentration of antibody-MORF in blood. Contrary to conclusions arrived at in our earlier study, the results of this study show that tumor CEA sites were not saturated even at the highest antibody dose investigated, that accessibility of MORF sites in tumor by 99mTc-cMORF was unhindered and that the maximum percent tumor accumulation of 99mTc-cMORF depended only on the tumor delivery efficiency of 99mTc-cMORF." @default.
• W2005098585 created "2016-06-24" @default.
• W2005098585 creator A5015860537 @default.
• W2005098585 creator A5017451995 @default.
• W2005098585 creator A5035945225 @default.
• W2005098585 creator A5068308808 @default.
• W2005098585 creator A5091137372 @default.
• W2005098585 creator A5091813705 @default.
• W2005098585 date "2005-08-20" @default.
• W2005098585 modified "2023-10-01" @default.
• W2005098585 title "Further investigations of morpholino pretargeting in mice—establishing quantitative relations in tumor" @default.
• W2005098585 cites W1504184527 @default.
• W2005098585 cites W1537791451 @default.
• W2005098585 cites W1573871285 @default.
• W2005098585 cites W1582946240 @default.
• W2005098585 cites W1846136289 @default.
• W2005098585 cites W1966192244 @default.
• W2005098585 cites W1974301585 @default.
• W2005098585 cites W1979150580 @default.
• W2005098585 cites W1987409259 @default.
• W2005098585 cites W1999237829 @default.
• W2005098585 cites W2026918336 @default.
• W2005098585 cites W2030765561 @default.
• W2005098585 cites W2050939126 @default.
• W2005098585 cites W2062239082 @default.
• W2005098585 cites W2109601059 @default.
• W2005098585 cites W2135136599 @default.
• W2005098585 cites W2156362732 @default.
• W2005098585 cites W2171291408 @default.
• W2005098585 cites W2184100701 @default.
• W2005098585 cites W2265959190 @default.
• W2005098585 cites W2286405748 @default.
• W2005098585 cites W2314148192 @default.
• W2005098585 cites W2399125703 @default.
• W2005098585 cites W4231724325 @default.
• W2005098585 doi "https://doi.org/10.1007/s00259-005-1853-5" @default.
• W2005098585 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1587614" @default.
• W2005098585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16133391" @default.
• W2005098585 hasPublicationYear "2005" @default.
• W2005098585 type Work @default.
• W2005098585 sameAs 2005098585 @default.
• W2005098585 citedByCount "31" @default.
• W2005098585 countsByYear W20050985852012 @default.
• W2005098585 countsByYear W20050985852013 @default.
• W2005098585 countsByYear W20050985852015 @default.
• W2005098585 countsByYear W20050985852016 @default.
• W2005098585 countsByYear W20050985852017 @default.
• W2005098585 countsByYear W20050985852018 @default.
• W2005098585 countsByYear W20050985852019 @default.
• W2005098585 countsByYear W20050985852020 @default.
• W2005098585 crossrefType "journal-article" @default.
• W2005098585 hasAuthorship W2005098585A5015860537 @default.
• W2005098585 hasAuthorship W2005098585A5017451995 @default.
• W2005098585 hasAuthorship W2005098585A5035945225 @default.
• W2005098585 hasAuthorship W2005098585A5068308808 @default.
• W2005098585 hasAuthorship W2005098585A5091137372 @default.
• W2005098585 hasAuthorship W2005098585A5091813705 @default.
• W2005098585 hasBestOaLocation W20050985852 @default.
• W2005098585 hasConcept C104317684 @default.
• W2005098585 hasConcept C112705442 @default.
• W2005098585 hasConcept C136571751 @default.
• W2005098585 hasConcept C159654299 @default.
• W2005098585 hasConcept C185592680 @default.
• W2005098585 hasConcept C202751555 @default.
• W2005098585 hasConcept C203014093 @default.
• W2005098585 hasConcept C2776146153 @default.
• W2005098585 hasConcept C2776878037 @default.
• W2005098585 hasConcept C2777807558 @default.
• W2005098585 hasConcept C2777836882 @default.
• W2005098585 hasConcept C542903549 @default.
• W2005098585 hasConcept C55493867 @default.
• W2005098585 hasConcept C71924100 @default.
• W2005098585 hasConcept C98274493 @default.
• W2005098585 hasConceptScore W2005098585C104317684 @default.
• W2005098585 hasConceptScore W2005098585C112705442 @default.
• W2005098585 hasConceptScore W2005098585C136571751 @default.
• W2005098585 hasConceptScore W2005098585C159654299 @default.
• W2005098585 hasConceptScore W2005098585C185592680 @default.
• W2005098585 hasConceptScore W2005098585C202751555 @default.
• W2005098585 hasConceptScore W2005098585C203014093 @default.
• W2005098585 hasConceptScore W2005098585C2776146153 @default.
• W2005098585 hasConceptScore W2005098585C2776878037 @default.
• W2005098585 hasConceptScore W2005098585C2777807558 @default.
• W2005098585 hasConceptScore W2005098585C2777836882 @default.
• W2005098585 hasConceptScore W2005098585C542903549 @default.
• W2005098585 hasConceptScore W2005098585C55493867 @default.
• W2005098585 hasConceptScore W2005098585C71924100 @default.
• W2005098585 hasConceptScore W2005098585C98274493 @default.
• W2005098585 hasIssue "9" @default.
• W2005098585 hasLocation W20050985851 @default.
• W2005098585 hasLocation W20050985852 @default.
• W2005098585 hasLocation W20050985853 @default.
• W2005098585 hasLocation W20050985854 @default.
• W2005098585 hasOpenAccess W2005098585 @default.
• W2005098585 hasPrimaryLocation W20050985851 @default.
• W2005098585 hasRelatedWork W1858303686 @default.
• W2005098585 hasRelatedWork W1971628265 @default.
• W2005098585 hasRelatedWork W1973774944 @default.

• next